Cardiovascular Risk Reduction With Icosapent Ethyl: A Systematic Literature Review

被引：3
作者：
Thakur, Mala [1 ]
Sangha, Pritpal S. [2 ]
Satti, Areesha [3 ]
Shah, Pooja N. [1 ]
机构：
[1] Xavier Univ, Sch Med, Internal Med, Oranjestad, Aruba
[2] Med Univ Lublin, Med, Lublin, Poland
[3] St James Sch Med, Internal Med, The Valley, Anguilla
来源：
CUREUS JOURNAL OF MEDICAL SCIENCE | 2020年 / 12卷 / 10期
关键词：
cardiovascular; icosapent ethyl; awareness of cardiovascular disease; diabetes mellitus; heart disease; statins; cholesterol; triglycerides; lipoproteins; DENSITY-LIPOPROTEIN CHOLESTEROL; HEART-FAILURE; HOSPITALIZATION; TRIGLYCERIDES; DISEASE; DEATH;
D O I：
10.7759/cureus.10942
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Cardiovascular disease is the leading cause of death in the United States of America due to elevated triglyceride levels. High triglyceride levels lead to higher risks of ischemic events. There are multiple pieces of research and analyses on statin therapy and its ability to reduce the prevalence of heart complications. Heart ailments can reduce through the use of icosapent ethyl in the form of statin therapy. This literature review will explain the reduction of cardiovascular risks with icosapent ethyl. Though some genetic conditions can cause some of these ailments, the rest of the predisposing conditions revolve around cholesterol, lipoproteins, and triglycerides.
引用
收藏
页数：8
相关论文
共 18 条
  • [1] [Anonymous], 2018, SMOKING YOUR HEART
  • [2] [Anonymous], 2020, VASCEPA
  • [3] Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
    Bain, Stephen C.
    Mosenzon, Ofri
    Arechavaleta, Rosario
    Bogdanski, Pawel
    Comlekci, Abdurrahman
    Consoli, Agostino
    Deerochanawong, Chaicharn
    Dungan, Kathleen
    Faingold, Maria C.
    Farkouh, Michael E.
    Franco, Denise R.
    Gram, Jeppe
    Guja, Cristian
    Joshi, Pankaj
    Malek, Rachid
    Merino-Torres, Juan F.
    Nauck, Michael A.
    Pedersen, Sue D.
    Sheu, Wayne H. -H.
    Silver, Robert J.
    Tack, Cees J.
    Tandon, Nikhil
    Jeppesen, Ole K.
    Strange, Mette
    Thomsen, Mette
    Husain, Mansoor
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (03) : 499 - 508
  • [4] High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions
    Barter, P
    Kastelein, J
    Nunn, A
    Hobbs, R
    [J]. ATHEROSCLEROSIS, 2003, 168 (02) : 195 - 211
  • [5] Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
    Basha, M. Aseem
    [J]. JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2019, 5 (01) : 44 - 47
  • [6] The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
    Basile, Jan N.
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2013, 27 (03) : 280 - 286
  • [7] Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)
    Braeckman, Rene A.
    Manku, Mehar S.
    Bays, Harold E.
    Stirtan, William G.
    Soni, Paresh N.
    [J]. PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2013, 89 (04): : 195 - 201
  • [8] Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
    Cavender, Matthew A.
    Steg, Ph Gabriel
    Smith, Sidney C., Jr.
    Eagle, Kim
    Ohman, E. Magnus
    Goto, Shinya
    Kuder, Julia
    Im, Kyungah
    Wilson, Peter W. F.
    Bhatt, Deepak L.
    [J]. CIRCULATION, 2015, 132 (10) : 923 - 931
  • [9] Enas EA, 2013, INDIAN J MED RES, V138, P461
  • [10] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial
    Fitchett, David
    Butler, Javed
    van de Borne, Philippe
    Zinman, Bernard
    Lachin, John M.
    Wanner, Christoph
    Woerle, Hans J.
    Hantel, Stefan
    George, Jyothis T.
    Johansen, Odd Erik
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (05) : 363 - 370
12